Alcohol Use Disorder Overview
Alcohol Use Disorder, also referred to as Alcoholism is the most severe form of alcohol abuse and involves the inability tomanage drinking habits. It is also known as Alcohol Addiction. These are common and potentially lethal disorders that mimic and exacerbate a wide range of additional medical and psychiatric conditions, and thereby shorten the lifespans of affected people by more than a decade.
“Alcohol Use Disorder Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Alcohol Use Disorder Market.
The Alcohol Use Disorder Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Alcohol Use Disorder Pipeline Report:
- Companies across the globe are diligently working toward developing novel Alcohol Use Disorder treatment therapies with a considerable amount of success over the years. Alcohol Use Disorder Key players such as - Pear Therapeutics, Cybin, Lohocla Research, BioXcel Therapeutics, Pop Test Oncology, Dicerna Pharmaceuticals, Astellas Pharma, Kinnov Therapeutics, MediciNova, Adial Pharmaceuticals, and others, are developing therapies for the Alcohol Use Disorder treatment
- Alcohol Use Disorder Emerging therapies such as - Pear-009, CYB003, Nezavist, BXCL501, PT150, DCR-AUD, ASP8062, KT 110, Ibudilast, AD04, and others are expected to have a significant impact on the Alcohol Use Disorder market in the coming years.
- On January 24, 2022, Adial Pharmaceuticals announced that the U.S. Patent and Trademark Office (USPTO) has mailed a Notice of Allowance for US Patent Application No. 16/784,051, a patent application for the treatment for opioid use disorder (OUD) using AD04. This patent application covers treatment of patients with a specific genetic biomarker for the serotonin-3 receptor
- In June 2021, Adial Pharmaceuticals FDA rejected its request for Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its drug candidate, AD04, for the treatment of Alcohol Use Disorder (AUD) in pediatric patients and adult patients with Alcoholic Liver Disease (ALD)with select polymorphisms of the serotonin transporter and receptor genes
- Adial Pharmaceuticals in February 2020, initiated randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of AD04 (Ondansetron) in adults with Alcohol Use Disorder (AUD) and Selected Polymorphisms in the Serotonin Transporter and Receptor Genes
Route of Administration
Alcohol Use Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravenous
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
Molecule Type
Products have been categorized under various Molecule types, such as
- Gene therapies
- Small molecule
- Vaccines
- Polymers
- Peptides
- Monoclonal antibodies
- Product Type
Alcohol Use Disorder Pipeline Therapeutics Assessment
- Alcohol Use Disorder Assessment by Product Type
- Alcohol Use Disorder By Stage and Product Type
- Alcohol Use Disorder Assessment by Route of Administration
- Alcohol Use Disorder By Stage and Route of Administration
- Alcohol Use Disorder Assessment by Molecule Type
- Alcohol Use Disorder by Stage and Molecule Type
DelveInsight's Alcohol Use Disorder Report covers around 5+ products under different phases of clinical development like-
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Some of the key companies in the Alcohol Use Disorder Therapeutics Market include:
Key companies developing therapies for Alcohol Use Disorder are - Alkermes, Teva Pharmaceutical Industries Ltd., BioCorRx, Inc., Adial Pharmaceuticals, ADDEX THERAPEUTICS, Kinnov Therapeutics, Opiant Pharmaceuticals, Ethypharm, Omeros Corporation, Montisera Ltd., and others
Emerging Alcohol Use Disorder Drugs Under Different Phases of Clinical Development Include:
- Pear-009: Pear Therapeutics
- CYB003: Cybin
- Nezavist: Lohocla Research
- BXCL501: BioXcel Therapeutics
- PT150: Pop Test Oncology
- DCR-AUD: Dicerna Pharmaceuticals
- ASP8062: Astellas Pharma
- KT 110: Kinnov Therapeutics
- Ibudilast: MediciNova
- AD04: Adial Pharmaceuticals
Get a Free Sample PDF Report to know more about Alcohol Use Disorder Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/alcohol-use-disorder-pipeline-insight
Alcohol Use Disorder Pipeline Analysis:
The Alcohol Use Disorder pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Alcohol Use Disorder with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alcohol Use Disorder Treatment.
- Alcohol Use Disorder key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Alcohol Use Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Alcohol Use Disorder market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Alcohol Use Disorder product details are provided in the report. Download the Alcohol Use Disorder pipeline report to learn more about the emerging Alcohol Use Disorder therapies
Alcohol Use Disorder Pipeline Market Drivers
- Increasing Awareness
- Increasing research and development
- Initiative taken by market players
Alcohol Use Disorder Pipeline Market Barriers
- Less Treatment Utilization
- Side Effects of The Current Therapies
Scope of Alcohol Use Disorder Pipeline Drug Insight
- Coverage: Global
- Key Alcohol Use Disorder Companies: Pear Therapeutics, Cybin, Lohocla Research, BioXcel Therapeutics, Pop Test Oncology, Dicerna Pharmaceuticals, Astellas Pharma, Kinnov Therapeutics, MediciNova, Adial Pharmaceuticals, and others
- Key Alcohol Use Disorder Therapies: Pear-009, CYB003, Nezavist, BXCL501, PT150, DCR-AUD, ASP8062, KT 110, Ibudilast, AD04, and others
- Alcohol Use Disorder Therapeutic Assessment: Alcohol Use Disorder current marketed and Alcohol Use Disorder emerging therapies
- Alcohol Use Disorder Market Dynamics: Alcohol Use Disorder market drivers and Alcohol Use Disorder market barriers
Request for Sample PDF Report for Alcohol Use Disorder Pipeline Assessment and clinical trials
Table of Contents
| 1 | Alcohol Use Disorder Report Introduction |
| 2 | Alcohol Use Disorder Executive Summary |
| 3 | Alcohol Use Disorder Overview |
| 4 | Alcohol Use Disorder- Analytical Perspective In-depth Commercial Assessment |
| 5 | Alcohol Use Disorder Pipeline Therapeutics |
| 6 | Alcohol Use Disorder Late Stage Products (Phase II/III) |
| 7 | Alcohol Use Disorder Mid Stage Products (Phase II) |
| 8 | Alcohol Use Disorder Early Stage Products (Phase I) |
| 9 | Alcohol Use Disorder Preclinical Stage Products |
| 10 | Alcohol Use Disorder Therapeutics Assessment |
| 11 | Alcohol Use Disorder Inactive Products |
| 12 | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13 | Alcohol Use Disorder Key Companies |
| 14 | Alcohol Use Disorder Key Products |
| 15 | Alcohol Use Disorder Unmet Needs |
| 16 | Alcohol Use Disorder Market Drivers and Barriers |
| 17 | Alcohol Use Disorder Future Perspectives and Conclusion |
| 18 | Alcohol Use Disorder Analyst Views |
| 19 | Appendix |
| 20 | About DelveInsight |
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report to know more about Alcohol Use Disorder drugs and therapies
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/r-and-d-analysis
